LY2140023 – Treatment of Schizophrenia

 
Key Data:
Drug (brand/generic)
LY2140023
Company/licensee
Eli Lilly
Therapy class
Glutamate agonist
Product description
Reduces presynaptic release of glutamate
Current indication
Treatment of schizophrenia
Market sector
CNS
Development status
Phase II

Return to Project



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development